The broad-spectrum antiviral recommendations for drug discovery against COVID-19

References

• Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. 2019. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Med. 13(1):126–130.
   PubMed Web of Science ®Google Scholar
• Amirian ES, Levy JK. 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 9:100128.
   PubMed Web of Science ®Google Scholar
• Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R, Navarrete-Macias I, Liang E, Wells H, Hicks A, et al. 2017. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. MBio. 8(2):e0037300317.
   Web of Science ®Google Scholar
• Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F. 2018. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 19(1):81.
   PubMedGoogle Scholar
• Bailly C. 2019. Cepharanthine: an update of its mode of action, pharmacological properties and medical applications. Phytomedicine. 62:152956.
   PubMed Web of Science ®Google Scholar
• Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky U, Day R, Garten W, et al. 2012. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem. 287(26):21992–22003.
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 4(6):1011–1033.
   PubMed Web of Science ®Google Scholar
• Beury D, Fléchon L, Maurier F, Caboche S, Varré J-S, Touzet H, Faure K, Dubuisson J, Hot D, Guery B, et al. 2020. Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit. J Clin Virol. 122:104206
   PubMed Web of Science ®Google Scholar
• Bhagya N, Chandrashekar K. 2016. Tetrandrine-A molecule of wide bioactivity. Phytochemistry. 125:5–13.
   PubMed Web of Science ®Google Scholar
• Bian C, Zhang X, Cai X, Zhang L, Chen Z, Zha Y, Xu Y, Xu K, Lu W, Yan L, et al. 2009. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology. 383(1):39–46.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Won JJ, Graham RL, Dinnon KH, III Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP. 2019. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169:104541.
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al. 2020. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. DOI:10.1016/j.eng.2020.03.007.
   Web of Science ®Google Scholar
• Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S, et al. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. J Cell Host Microbe. 19(2):181–193.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J. 2020. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. DOI:10.1101/2020.03.17.20037432.
   Google Scholar
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Chen YW, Yiu C-P, Wong K-Y. 2020. Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. ChemRxiv. DOI:10.26434/chemrxiv.11831103.v1.
   Google Scholar
• Chong YP, Song JY, Seo YB, Choi J-P, Shin H-S, Team RR. 2015. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 47(3):212–222.
   PubMed Web of Science ®Google Scholar
• Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, et al. 2020. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 295(1):202–207.
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. 2003. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. The Lancet. 361(9374):2045–2046.
   PubMed Web of Science ®Google Scholar
• Comar CE, Goldstein SA, Li Y, Yount B, Baric RS, Weiss SR. 2019. Antagonism of dsRNA-induced innate immune pathways by NS4a and NS4b accessory proteins during MERS coronavirus infection. MBio. 10(2):e00319–00319.
   PubMed Web of Science ®Google Scholar
• Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, Fernandez-Rodriguez B, Foglierini M, Agatic G, Vanzetta F, et al. 2015. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci Usa. 112(33):10473–10478.
   PubMed Web of Science ®Google Scholar
• Cui J, Li F, Shi Z-L. 2019. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 17(3):181–192.
   PubMed Web of Science ®Google Scholar
• Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A. 2016. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment . EMBO Mol Med. 8(9):1099–1112.
   PubMed Web of Science ®Google Scholar
• De Martin E, Michot J-M, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, et al. 2018. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 68(6):1181–1190.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. 2017. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 419:1–42.
   Web of Science ®Google Scholar
• de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson KJ, Stahl N, Lipsich L, et al. 2018. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 156:64–71.
   PubMed Web of Science ®Google Scholar
• Deng X, van Geelen A, Buckley AC, O’Brien A, Pillatzki A, Lager KM, Faaberg KS, Baker SC. 2019. Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses. J Virol. 93(8):e02000–02018.
   PubMed Web of Science ®Google Scholar
• Du Toit A. 2020. Outbreak of a novel coronavirus. Nat Rev Microbiol. 18(3):123–123.
   PubMed Web of Science ®Google Scholar
• Du YX, Chen XP. 2020. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clin Pharmacol Ther. DOI:10.1002/cpt.1844.
   Web of Science ®Google Scholar
• Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, et al. 2013. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 19(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 8(4):e21.
   PubMed Web of Science ®Google Scholar
• Frieman M, Jarhling PB, Hensley LE. 2019. Methods of treating coronavirus infection. Google Patents.
   Google Scholar
• Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. DOI:10.1016/j.ijantimicag.2020.105949.
   PubMed Web of Science ®Google Scholar
• Graham BS, Gilman MS, McLellan JS. 2019. Structure-Based vaccine antigen design. Annu Rev Med. 70:91–104.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Menachery VD. 2020. Return of the Coronavirus: 2019-nCoV. Viruses. 12(2):135.
   PubMed Web of Science ®Google Scholar
• Güler HI, Tatar G, Yildiz O, Belduz AO, Kolayli S. 2020. An investigation of ethanolic propolis extracts: Their potential inhibitor properties against ACE-II receptors for COVID-19 treatment by Molecular Docking Study. ScienceOpen Preprints. DOI:10.14293/S2199-1006.1.SOR-.PP5BWN4.v1.
   Google Scholar
• Harismah K, Mirzaei M. 2020. Favipiravir: structural analysis and activity against COVID-19. Adv J Chem, Section B. 2(2):55–60.
   Google Scholar
• He L, Tai W, Li J, Chen Y, Gao Y, Li J, Sun S, Zhou Y, Du L, Zhao G. 2019. Enhanced ability of oligomeric nanobodies targeting MERS coronavirus receptor-binding domain. Viruses. 11(2):166.
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, Feldmann H. 2019. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 17(10):593–606.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395(10223):497–506.,
   PubMed Web of Science ®Google Scholar
• Ito S, Kayukawa N, Ueda T, Taniguchi H, Morioka Y, Hongo F, Ukimura O. 2018. MRGBP promotes AR-mediated transactivation of KLK3 and TMPRSS2 via acetylation of histone H2A. Z in prostate cancer cells. Biochimica et Biophysica Acta -Gene Regulatory Mechanisms. 1861(9):794–802.
   Web of Science ®Google Scholar
• Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, DeWald LE, Schornberg KL, Scully C, et al. 2013. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 5(190):190ra79– 190ra179.
   PubMed Web of Science ®Google Scholar
• Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. 2012. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 86(12):6537–6545.
   PubMed Web of Science ®Google Scholar
• Kim DE, Min JS, Jang MS, Lee JY, Shin YS, Park CM, Song JH, Kim HR, Kim S, Jin Y-H. 2019. Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells. Biomolecules. 9(11):696.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. 2016. Case report Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther (Lond).). 21(5):455–459.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee H, Park K, Park S, Lim J-H, So MK, Woo H-M, Ko H, Lee J-M, Lim SH. 2019. Selection and characterization of monoclonal antibodies targeting middle east respiratory syndrome coronavirus through a human synthetic Fab Phage Display Library Panning. Antibodies. 8(3):42.
   Web of Science ®Google Scholar
• Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB. 2016. Pre-fusion structure of a human coronavirus spike protein. Nature. 531(7592):118–121.
   PubMed Web of Science ®Google Scholar
• Kumaki Y, Salazar AM, Wandersee MK, Barnard DL. 2017. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol®(Poly IC: LC), in a lethal SARS-CoV-infected BALB/c mouse model. Antivir Res. 139:1–12.
   PubMed Web of Science ®Google Scholar
• Kumar V, Shin JS, Shie J-J, Ku KB, Kim C, Go YY, Huang K-F, Kim M, Liang P-H. 2017. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 141:101–106.
   PubMed Web of Science ®Google Scholar
• Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 55(3):105924.
   PubMed Web of Science ®Google Scholar
• Lau SK, Woo PC, Li KS, Huang Y, Tsoi H-W, Wong BH, Wong SS, Leung S-Y, Chan K-H, Yuen K-Y. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci. 102(39):14040–14045.
   PubMed Web of Science ®Google Scholar
• Li J-Y, You Z, Wang Q, Zhou Z-J, Qiu Y, Luo R, Ge X-Y. 2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 22(2):80–85.
   PubMed Web of Science ®Google Scholar
• Li J, Liu W. 2020. Puzzle of highly pathogenic human coronaviruses (2019-nCoV). Protein Cell. 11(4):235–234.
   PubMed Web of Science ®Google Scholar
• Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, et al. 2015. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25(11):1237–1249.
   PubMed Web of Science ®Google Scholar
• Li Z, Tomlinson AC, Wong AH, Zhou D, Desforges M, Talbot PJ, Benlekbir S, Rubinstein JL, Rini JM. 2019. The human coronavirus HCoV-229E S-protein structure and receptor binding. Elife. 8:e51230.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Lin S-C, Hsu J-N, Chang C-k, Chien C-M, Wang Y-S, Wu H-Y, Jeng U-S, Kehn-Hall K, Hou M-H. 2020. Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. J Med Chem. 63(6):3131–3141.
   PubMed Web of Science ®Google Scholar
• Lin S, Shen R, He J, Li X, Guo X. 2020. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome Coronavirus 2 proteases. bioRxiv. DOI:10.1101/2020.01.31.929695.
   Google Scholar
• Lipsitch M, Swerdlow DL, Finelli L. 2020. Defining the epidemiology of Covid-19 – studies needed. N Engl J Med. 382(13):1194–1196.
   PubMed Web of Science ®Google Scholar
• Liu T, Liu X, Li W. 2016. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 7(26):40800–40815.
   PubMedGoogle Scholar
• Loveday E-K, Diederich S, Pasick J, Jean F. 2015. Human microRNA-24 modulates highly pathogenic avian-origin H5N1 influenza A virus infection in A549 cells by targeting secretory pathway furin. J Gen Virol. 96(Pt 1):30–39.
   PubMedGoogle Scholar
• Lu C-C, Chen M-Y, Chang Y-L. 2020. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. DOI:10.1097/JCMA.0000000000000318.
   Web of Science ®Google Scholar
• Lu L, Liu Q, Zhu Y, Chan K-H, Qin L, Li Y, Wang Q, Chan JF-W, Du L, Yu F, et al. 2014. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 5(1):1–12.
   Google Scholar
• Luk HK, Li X, Fung J, Lau SK, Woo PC. 2019. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 71:21–30.
   PubMed Web of Science ®Google Scholar
• Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, et al. 2013. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 8(4):e60579.
   PubMed Web of Science ®Google Scholar
• Majumder MS, Rivers C, Lofgren E, Fisman D. 2014. Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Curr.
   PubMedGoogle Scholar
• Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S, Nicoletti F. 2017. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Int J Cancer. 140(8):1713–1726.
   PubMed Web of Science ®Google Scholar
• Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, Coppes RP, Engedal N, Mari M, Reggiori F. 2018. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 14(8):1435–1455.
   PubMed Web of Science ®Google Scholar
• Menachery VD, Dinnon KH, Yount BL, McAnarney ET, Gralinski LE, Hale A, Graham RL, Scobey T, Anthony SJ, Wang L, et al. 2019. Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. J Virol. 94(5):e01774-19.
   Web of Science ®Google Scholar
• Meyer D, Sielaff F, Hammami M, Böttcher-Friebertshäuser E, Garten W, Steinmetzer T. 2013. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J. 452(2):331–343.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. 2015. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 202:120–134.
   PubMed Web of Science ®Google Scholar
• Mo Y, Fisher D. 2016. A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother. 71(12):3340–3350.
   PubMed Web of Science ®Google Scholar
• Neuman BW, Chamberlain P, Bowden F, Joseph J. 2014. Atlas of coronavirus replicase structure. Virus Res. 194:49–66.
   PubMed Web of Science ®Google Scholar
• Nguyen THV, Lichiere J, Canard B, Papageorgiou N, Attoumani S, Ferron F, Coutard B. 2019. Structure and oligomerization state of the C-terminal region of the middle east respiratory syndrome coronavirus nucleoprotein. Acta Crystallogr D Struct Biol. 75(Pt 1):8–15.
   PubMedGoogle Scholar
• Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM. 2014. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 14(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Organization WH. 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
   Google Scholar
• Organization WH. 2017. Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV in Republic of Korea at a glance.
   Google Scholar
• Organization WH. 2018. 2018 Annual review of diseases prioritized under the Research and Development Blueprint.
   Google Scholar
• Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, et al. 2015. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA. 112(28):8738–8743.
   PubMed Web of Science ®Google Scholar
• Pillaiyar T, Manickam M, Jung S. 2015. Middle East respiratory syndrome-coronavirus (MERS-CoV): an updated overview and pharmacotherapeutics. Med Chem. 5(8):361–372.
   Google Scholar
• Rabaan AA, Bazzi AM, Al-Ahmed SH, Al-Tawfiq JA. 2017. Molecular aspects of MERS-CoV. Front Med. 11(3):365–377.
   PubMed Web of Science ®Google Scholar
• Rahman H. 2018. MERS-CoV: Identifying Viral and Host Factors Associated with Transmission, Pathogenesis, and Treatment Development. Jemi Pearls. 3:23–31.
   Google Scholar
• Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, Dijkman R, Muth D, Demmers JAA, Zaki A, Fouchier RAM, et al. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 495(7440):251–254.
   PubMed Web of Science ®Google Scholar
• Rao P, Shukla A, Parmar P, Goswami D. 2020. Proposing a fungal metabolite-Flaviolin as a potential inhibitor of 3CLpro of novel coronavirus SARS-CoV2 using docking and molecular dynamics. arXiv preprint arXiv:03806.
   Google Scholar
• Sakurai Y, Kolokoltsov AA, Chen C-C, Tidwell MW, Bauta WE, Klugbauer N, Grimm C, Wahl-Schott C, Biel M, Davey RA. 2015. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science. 347(6225):995–998.
   PubMed Web of Science ®Google Scholar
• Sarma P, Sekhar N, Prajapat M, Avti P, Kaur H, Kumar S, Singh S, Kumar H, Prakash A, Dhibar DP. 2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn. DOI:10.1080/07391102.2020.1753580.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, et al. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et al. 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. 2017. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 142:1–10.
   PubMed Web of Science ®Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. 2011. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 85(2):873–882.
   PubMed Web of Science ®Google Scholar
• Snijder E, Decroly E, Ziebuhr J. 2016. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 96:59–126.
   PubMed Web of Science ®Google Scholar
• Tang X-C, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico ASC, Sheehan J, Zhu Q, et al. 2014. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci Usa. 111(19):E2018–E2026.
   PubMed Web of Science ®Google Scholar
• Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, et al. 2020. On the origin and continuing evolution of SARS-CoV-2. Nati Sci Rev. DOI:10.1093/nsr/nwaa036.
   PubMed Web of Science ®Google Scholar
• Totura AL, Bavari S. 2019. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 14(4):397–412.
   PubMed Web of Science ®Google Scholar
• Ulasli M, Verheije MH, de Haan CA, Reggiori F. 2010. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell Microbiol. 12(6):844–861.
   PubMed Web of Science ®Google Scholar
• Vivithanaporn P, Asahchop EL, Acharjee S, Baker GB, Power C. 2016. HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance. AIDS. 30(4):543.
   PubMed Web of Science ®Google Scholar
• Vlasova AN, Wang Q, Jung K, Langel SN, Malik YS, Saif LJ. 2020. Porcine Coronaviruses. In: Malik YS, Singh RK, Yadav MP, editors. Emerging and Transboundary Animal Viruses. Singapore: Springer; p. 79–110.
   Google Scholar
• Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, Rey FA, DiMaio F, Bosch B-J, Veesler D. 2016. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol. 23(10):899–905.
   PubMed Web of Science ®Google Scholar
• Wan Z, Lu Y, Liao Q, Wu Y, Chen X. 2012. Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing. PLoS One. 7(6):e39225.
   PubMed Web of Science ®Google Scholar
• Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, et al. 2015. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 6(1):1–11.
   Google Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• WHO. 2020. Novel Coronavirus (COVID-19) Situation. Geneva: WHO.
   Google Scholar
• Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S. 2014. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 194:200–210.
   PubMed Web of Science ®Google Scholar
• Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng C-TK, Wang Q, Du L, Tan W, Wilson IA, et al. 2019. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 5(4):eaav4580.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S. 2020. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. DOI:10.1038/s41423-020-0374-2.
   Web of Science ®Google Scholar
• Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue J-i, Matsuda Z. 2016. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 60(11):6532–6539.
   PubMed Web of Science ®Google Scholar
• Yu X, Zhang S, Jiang L, Cui Y, Li D, Wang D, Wang N, Fu L, Shi X, Li Z, et al. 2015. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci Rep. 5:13133.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, Lu G, Wu Y, Yan J, Shi Y, et al. 2017. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun. 8:15092.
   PubMed Web of Science ®Google Scholar
• Zeng L-P, Gao Y-T, Ge X-Y, Zhang Q, Peng C, Yang X-L, Tan B, Chen J, Chmura AA, Daszak P, et al. 2016. Bat severe acute respiratory syndrome-like coronavirus WIV1 encodes an extra accessory protein, ORFX, involved in modulation of the host immune response. J Virol. 90(14):6573–6582.
   PubMed Web of Science ®Google Scholar
• Zeng Z-Q, Chen D-H, Tan W-P, Qiu S-Y, Xu D, Liang H-X, Chen M-X, Li X, Lin Z-S, Liu W-K, et al. 2018. Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol Infect Dis. 37(2):363–369.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, et al. 2003. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 52(Pt 8):715–720.
   PubMed Web of Science ®Google Scholar
• Zheng M, Song L. 2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 17(5):536–538.
   PubMed Web of Science ®Google Scholar
• Zhou D, Qi R, Zhang W. 2020. Accessible surface glycopeptide motifs on spike glycoprotein of 2019-nCoV: implications on vaccination and antibody therapeutics. Preprints. DOI:10.20944/preprints202002.0381.v2.
   Google Scholar
• Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, et al. 2016. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 291(17):9218–9232.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, et al. 2015. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 116:76–84.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. 2016. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 15(5):327–347.
   PubMed Web of Science ®Google Scholar